Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a listen-only mode. [Operator instructions] After today's presentation, there will be an opportunity to ask questions.
Verona Pharma Q3 2024 Earnings Preview
Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.
Vertex Pharmaceuticals price target raised to $451 from $437 at RBC Capital
RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $451 from $437 but keeps a Sector Perform rating on the
Vertex Pharmaceuticals Tops Q3 Estimates
Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Recent Focus. Vertex Pharmaceuticals is renowned for its leadership in the cystic fibrosis mar
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and
Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago. These figures are adjusted for non-recurring items.
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may already be fully reflected. Learn more on VRTX stock here.
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...
pharmaphorum1d
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Raleigh pharma's stock hits record high amid drug launch
Verona Pharma (Nasdaq: VRNA) is already recording millions of dollars in revenue after launching its lead drug in August ...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
pharmaphorum2d
Verona cues up filings for COPD drug after it aces phase 3 test
UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.
Verona Pharma Reports Strong Q3 Launch for COPD Drug
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona ...